Medytox wins sales approval for BTX, HA filler abroad

Medytox said that it has obtained additional sales approvals for Medytoxin, its botulinum toxin (BTX) product, and Neuramis, its hyaluronic acid (HA) filler.

Medytox has obtained additional overseas sales approvals for Medytoxin and Neuramis. (Medytox)

Medytoxin won sales approval in Saudi Arabia and Malaysia. “The aesthetic demand is growing in the two countries with the middle classes' growth,” the company said. “The two nations can serve as beachheads to advance to the Islamic market. We will accelerate expansion into other Islamic countries based on its sales know-how accumulated in the two countries.”

Besides, Medytox has expanded its market base for Neuramis to 44 countries after obtaining marketing nods in Brazil and the Philippines.

“We will maximize synergy based on the recognition of Medytoxin, which achieved a 40 percent market share in the Brazilian market in four years of its launch,” a company official said. “We are also planning to obtain marketing permits in Taiwan, Mexico, and El Salvador within this year, to make Neuramis a global filler brand by making the most of its European certifications.”

The official added that the company is trying to preempt these markets using a customized strategy based on its overseas expansion experience.